Surprisingly, blocking a signaling molecule called IL-9 helps mice clear the Pneumocystis fungus better — it seems IL-9 normally puts the brakes on a helpful immune response.
Claim Context
IL-9 signaling appears to negatively regulate protective immunity against Pneumocystis in mice, as IL-9-deficient mice show reduced fungal burden and enhanced Th17 responses, suggesting IL-9 may suppress Th17-mediated fungal clearance.
“Il‐9 −/− mice exhibit no significant difference in the final clearance of Pneumocystis organisms from lung tissues; these gene‐depleted mice demonstrate a markedly reduced pulmonary fungal burden 3 weeks after Pneumocystis infection compared with that observed in WT mice... suggesting an enhanced...”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether blocking IL-9 improves fungal clearance in immunocompromised humans with PCP.
A phase I/II double-blind RCT of 40 immunocompromised patients with PCP, randomized to receive anti-IL-9 monoclonal antibody (10 mg/kg IV weekly) or placebo for 4 weeks, with primary outcome: change in BAL fungal burden (qPCR) at day 14.
Whether high IL-9 levels in BAL fluid correlate with higher fungal burden and lower Th17 activity in human PCP.
A prospective cohort of 120 immunocompromised patients with PCP, measuring IL-9 and IL-17A levels in BAL fluid at diagnosis and during treatment, correlating with fungal burden and clinical recovery.
Whether patients with chronic mucocutaneous candidiasis (low IL-9) have lower PCP incidence than expected.
A matched case-control study of 50 patients with chronic mucocutaneous candidiasis (known IL-9 deficiency) and 100 immunocompromised controls, assessing PCP incidence over 5 years.
Whether IL-9 expression is elevated in the lungs of PCP patients compared to healthy controls or those with other fungal infections.
A cross-sectional analysis of lung tissue or BAL fluid from 60 patients: 20 with PCP, 20 with Aspergillus, 20 with no infection, measuring IL-9 mRNA and protein levels.
Clinical course of PCP in patients with rare IL-9 pathway mutations.
A case series of 3 patients with confirmed IL-9 or PU.1 mutations who develop PCP, documenting immune cell profiles and fungal burden.